代谢综合征、糖尿病和糖尿病前期对心血管事件的影响：德黑兰血脂和血糖研究。

Impact of metabolic syndrome, diabetes and prediabetes on cardiovascular events: Tehran lipid and glucose study.

机构信息

Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Diabetes Res Clin Pract. 2010 Mar;87(3):342-7. doi: 10.1016/j.diabres.2009.11.010. Epub 2009 Dec 8.

DOI:10.1016/j.diabres.2009.11.010

PMID:20004035

Abstract

AIMS

To compare the cardiovascular disease (CVD) risk associated with the metabolic syndrome (MetS) and dysglycemia, independent of each other during a median follow-up of 6.7 years.

METHODS

Study population included 4018 Iranian subjects >or=40 years, free of CVD or coronary heart disease (CHD) at baseline. Incidence rates and hazard ratio (HR) were estimated by the presence or absence of MetS and dysglycemia. Considering the glycemic status, the ability of MetS in prediction of CVD after adjustment for age, sex and CVD risk factors was assessed.

RESULTS

The prevalence of MetS, impaired fasting glucose or impaired glucose tolerance (IFG/IGT) and diabetes were 51.4%, 27.3%, and 18.7%, respectively. The addition of MetS to diabetes did not change the CVD risk compared to diabetic subjects without MetS (reference group) after adjustment for age and sex [HR: 1.62 (95% CI 0.93-2.81)] and CVD risk factors [HR: 1.49 (95% CI 0.86-2.60)]. However, addition of MetS to IFG/IGT increased the risk of CVD by 2.5 times compared to those with IFG/IGT without MetS (the risk factor adjusted HR: 2.45 (95% CI 1.32-4.55)).

CONCLUSIONS

In Iranian population, MetS did not add to diabetes to predict incident CVD however, IFG/IGT was a significant predictor only in the presence of MetS.

摘要

目的

在中位随访 6.7 年期间，比较代谢综合征（MetS）和糖代谢异常与心血管疾病（CVD）风险的相关性，且彼此独立。

方法

研究人群包括 4018 名年龄≥40 岁的伊朗受试者，基线时无 CVD 或冠心病（CHD）。通过存在或不存在 MetS 和糖代谢异常来估计发生率和风险比（HR）。考虑到血糖状态，评估 MetS 在调整年龄、性别和 CVD 危险因素后对 CVD 预测的能力。

结果

MetS、空腹血糖受损或糖耐量受损（IFG/IGT）和糖尿病的患病率分别为 51.4%、27.3%和 18.7%。在调整年龄和性别后，将 MetS 与糖尿病相加不会改变与无 MetS 的糖尿病患者（参考组）的 CVD 风险[HR：1.62（95%CI 0.93-2.81）]和 CVD 危险因素[HR：1.49（95%CI 0.86-2.60）]。然而，将 MetS 与 IFG/IGT 相加会使无 MetS 的 IFG/IGT 患者的 CVD 风险增加 2.5 倍（调整危险因素的 HR：2.45（95%CI 1.32-4.55））。